Up to date treatment of ascites in liver cirrhosis

Document Type : Original Article

Authors

Department of Internal Medicine, Faculty of Medicine, Sohag University.

Main Subjects

References

  1. Planas R, Montoliu S, Ballesté B, et al. Natural history of patients hospitalized for management of cirrhotic ascites. Clin Gastroenterol Hepatol. 2006;4:1385-94.
  2. Runyon BA; AASLD Practice Guidelines Committee. Management of adult patients with ascites due to cirrhosis: update 2012. [AASLD Practice Guidelines].
  3. Fede G, D'Amico G, Arvaniti V, et al. Renal failure and cirrhosis: a systematic review of mortality and prognosis. J Hepatol. 2012 Apr. 56(4):810-8.
  4. Casado, M, Bosch, J, and García-Pagán JC. Clinical events after transjugular intrahepatic portosystemic shunt: correlation with hemodynamic findings. Gastroenterology. 1998;114(6):1296-1303.
  5. Arroyo V. Pathophysiology, diagnosis and treatment of ascites in cirrhosis. Annals of Hepatology. 2002;1(2):72-79.
  6. Gentilini P, Vizzutti F, Gentilini A,  et al. Update on ascites and hepatorenal syndrome. Digestive and Liver Disease. 2002;34(8):592-605.
  7. Fukui H. Do vasopressin V2 receptor antagonists benefit cirrhotics with refractory ascites? World J Gastroenterol. 2015; 21(41):11584 11596.
  8. Moore KP, Wong F, Gines P, et al.The management of ascites in cirrhosis: Report on the consensus conference the International Ascites Club. Hepatology. 2003;38(1):258-266.
  9. Sola E, Sole C and Gines P. Management of uninfected and infected ascites in cirrhosis. Liver Int. 2016;36 Suppl 1:109–115.
  10. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis Journal of Hepatology 2018 vol. 69 j 406–460.
  11. Runyon BA and Aasld. Introduction to the revised American Association for the Study of Liver Diseases Practice Guideline management of adult patients with ascites due to cirrhosis 2012. Hepatology 2013; 57: 1651–1653.
  12. Santos J, Planas R, Pardo A, et al. Spironolactone alone or in combination with furosemide in the treatment of moderate ascites in nonacademic cirrhosis. A randomized comparative study of efficacy and safety. Journal of Hepatology. 2003;39(2):187-192.
  13. Pache I and Bilodeau M. Severe hemorrhage following abdominal paracentesis for ascites in patients with liver disease. Alimentary Pharmacology & Therapeutics. 2005;21(5):525-529.
  14. Alessandria C, Elia C, Mezzabotta L, et al. Prevention of paracentesis-induced circulatory dysfunction in cirrhosis: standard vs half albumin doses. A prospective, randomized, unblinded pilot study. Dig Liver Dis. 2011;43(11):881–886.
  15. Rossel M, Ochs A, Gulberg V, et al. A comparison of paracentesis and transjugular intrahepatic portosystemic shunting in patients with ascites. New England Journal of Medicine. 2000;342(23):1701-1707
  16. Deltenre P, Mathurin P, Dharancy S, et al. Transjugular intrahepatic portosystemic shunt in refractory ascites: a meta-analysis. Liver Int 2005; 25: 349–356.
  17. Rossel M. TIPS: 25 years later. Journal of Hepatology. 2013;59(5):1081-1093.
  18. La Mura V and Salerno F. Therapy of the refractory ascites: Total paracentesis vs. TIPS. Gastroenterología y Hepatología  2015;39(7):477-480.
  19. Saab S, Nieto JM, Lewis SK, et al. TIPS versus paracentesis for cirrhotic patients with refractory ascites. The Cochrane Database of Systematic Reviews. 2006;(4):CD004889 .
  20. Salerno F, Cammà C, Enea M, et al. Transjugular intrahepatic portosystemic shunt for refractory ascites: A meta‐analysis of individual patient data. Gastroenterology. 2007;133(3):825-834.
  21. Boyer TD and Haskal ZJ, D. American Association for the Study of Liver. The role of a transjugular intrahepatic portosystemic shunt in the management of portal hypertension. Hepatology. 2005;41(2):386-400.
  22. Fukui H, Saito H, Ueno Y, et al. Evidence-based clinical practice guidelines for liver cirrhosis 2015. J Gastroenterol 2016; 7: 629–650.
  23. Inoue N, Yamazaki Z, Oda T, et al. Treatment of intractable ascites by continuous reinfusion of the sterilized, cell-free and concentrated ascitic fluid. Transactions - American Society for Artificial Internal Organs 1977; 23: 699–702.
  24. Zaak D, Paquet KJ and Kuhn R. Prospective study comparing human albumin vs. reinfusion of ultrafiltrate-ascitic fluid after total paracentesis in cirrhotic patients with tense ascites. Z Gastroenterol. 2001;39(1):5–10.
  25. Bellot P, Welker MW, Soriano G, et al. Automated low flow pump system for the treatment of refractory ascites: a multi-center safety and efficacy study. J Hepatol 2013;58:922–927.
  26. Stirnimann G, Berg T, Spahr L, et al. Treatment of refractory ascites with an automated low-flow ascites pump in patients with cirrhosis. Aliment Pharmacol Ther 2017;46:981–991.
  27. Bureau C, Adebayo D, Chalret de Rieu M, et al. Alfapump_ system vs. large volume paracentesis for refractory ascites: A multicenter randomized controlled study. J Hepatol 2017;67:940–949.
  28. Sola E, Sanchez-Cabus S, Rodriguez E, et al. Effects of alfapump system on kidney and circulatory function in patients with cirrhosis and refractory ascites. Liver Transpl 2017;23:583–593.
  29. Hariprasad MK, Paul PK, Eisinger RB, et al.  Extracorporeal dialysis of ascites. A new technique. Arch Intern Med 1981; 141: 1550–1551.
  30. Raju SF and Achord JL. The effects of dialytic ultrafiltration and peritoneal reinfusion in the management of diuretic resistant ascites. Am J Gastroenterol 1984; 79: 308–312.
  31. Brett Fortune and Andres Cardenas. Ascites, refractory ascites, and hyponatremia in cirrhosis. Gastroenterology Report 2017;5(2): 104–112  

 

 

 

 

 

 

 

 

 

 

Files

Share

How to cite

Statistics